Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study

INTRODUCTION: The 1-, 3- and 6- month biodegradable polymer matrix depot formulations of leuprorelin acetate (Eligard(®)/Depo-Eligard(®), Astellas Pharma Inc/BV) were shown to reduce testosterone and prostate-specific antigen levels and to be well tolerated in patients with advanced prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Braeckman, Johan, Michielsen, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107255/
https://www.ncbi.nlm.nih.gov/pubmed/25097577
http://dx.doi.org/10.5114/aoms.2014.43743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107255/
https://www.ncbi.nlm.nih.gov/pubmed/25097577
http://dx.doi.org/10.5114/aoms.2014.43743

Ejemplares similares